Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13155409 | 0.79 | MAPK1 (0.38) | KDM4ETP53ALDH1A1MAPTMAPK1 | |
| SCHEMBL21722938 | 0.69 | — | — | |
| SCHEMBL10400097 | 0.69 | — | — | |
| SCHEMBL21722841 | 0.69 | MAPT (0.36) | ALDH1A1TSHRALOX15MAPTMAPK1 | |
| SCHEMBL11322083 | 0.69 | KDM4E (0.40) | TDP1KDM4EALDH1A1TSHRALOX15 | |
| SCHEMBL162059 | 0.69 | — | — | |
| SCHEMBL162060 | 0.69 | — | — | |
| SCHEMBL20928813 | 0.67 | — | — | |
| SCHEMBL26103133 | 0.67 | — | — | |
| SCHEMBL13954549 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| CN-114945571-B | Cyclic compounds and methods of use thereof | 薛定谔公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-10-17 | — | — | US | disclosed |
| CN-118666832-A | Urea compounds and compositions as SMARCA2/BRM atpase inhibitors | 诺华股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| WO-2024178127-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-08-29 | — | — | WO | disclosed |
| US-20240270738-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2024-08-15 | — | — | US | disclosed |
| CN-112585136-B | Urea compounds and compositions as SMARCA2/BRM atpase inhibitors | 诺华股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2024-04-16 | — | — | US | disclosed |
| CN-117779129-A | Electronic electroplating rhodium alloy solution, preparation method and electroplating method | 昆山一鼎工业科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | SCHRÖDINGER, INC. | 2024-01-18 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060205732-A1 | Heterocyclic carboxamides and their use as fungicides | BAYER SAS (FR) | 2006-09-14 | — | — | US | disclosed |
| US-7084163-B2 | Heterocyclic carboxamides and their use as fungicides | BAYER CROPSCIENCE S.A. (FR) | 2006-08-01 | — | — | US | disclosed |
| US-20040152698-A1 | Heterocyclic carboxamides and their use as fungicides | BAYER SAS (FR) | 2004-08-05 | — | — | US | disclosed |
| EP-1425276-A2 | HETEROCYCLIC CARBOXAMIDES AND THEIR USE AS FUNGICIDES | Bayer CropScience S.A. (FR) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003006454-A2 | HETEROCYCLIC CARBOXAMIDES AND THEIR USE AS FUNGICIDES | BAYER CROPSCIENCE S.A. (FR) | 2003-01-23 | — | — | WO | disclosed |
| EP-1275301-A1 | Trisubstituted heterocyclic compounds and their use as fungicides | Bayer CropScience S.A. (FR) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | IRF3, BCL3, L3MBTL3 | CASP6 949/4885TDP1 4829/4885KDM4E 1943/4885 |
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | CASP6 3410/4885TDP1 1379/4885KDM4E 1457/4885 |
| US-20040152698-A1 | Heterocyclic carboxamides and their use as fungicides | CYP1A2, CYP4X1, CYCS | CASP6 332/4885TDP1 2440/4885KDM4E 543/4885 |
| US-20240343710-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | CASP6 610/4885TDP1 33/4885KDM4E 1701/4885 |
| US-20060205732-A1 | Heterocyclic carboxamides and their use as fungicides | CYP4X1, CYP1A2, CYCS | CASP6 318/4885TDP1 2646/4885KDM4E 501/4885 |
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | CASP6 2827/4885TDP1 1618/4885KDM4E 1478/4885 |
| US-20240270738-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | SMARCC1, SMARCC2, SMARCA1 | CASP6 2756/4885TDP1 1533/4885KDM4E 1382/4885 |
| US-20240018157-A1 | CYCLIC COMPOUNDS AND METHODS OF USING SAME | MALT1, FKBP1B, FKBP1A | CASP6 1621/4885TDP1 429/4885KDM4E 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.